Latest News

According to phase 2 results from the CITADEL-204 study, durable responses and overall manageable safety was observed among patients with relapsed/refractory marginal zone lymphoma treated with parsaclisib monotherapy.

According to results from the phase 3 NORA trial, presented at the 2024 SGO meeting, an individualized starting dose of niraparib in the maintenace setting yielded a favorable overall survival trend, compared to placebo, among patients with...

On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

The novel myeloma CAR T Relapse prognostic model may be useful in strategizing optimal timing of CAR T-cell therapy in certain subgroups of patients with R/R MM, according to an international, retrospective study.

First-line therapy with immune checkpoint inhibition plus chemotherapy did not significantly improve overall survival or progression-free survival compared to immune checkpoint inhibition alone among older patients with advanced non-small...

According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.

According to phase 2 results, camrelizumab plus famitinib improved survival outcomes among patients with recurrent/metastatic cervical cancer, compared with camrelizumab alone and investigators choice of chemotherapy.

According to a phase 3 trial, the addition of induction chemotherapy prior to chemoradiation improved the progression-free survival and overall survival among patients locally advanced cervical cancer.

According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...

According to results from a phase 3 trial presented at the 2024 SGO Annual Meeting on Women’s Cancer, the addition of atezolizumab to first-line bevacizumab and chemotherapy improved progression-free survival, overall survival, and objective...